ClinicalTrials.gg
CompletedNCT07845266Updated Sep 28, 2026

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma

A Phase 1 interventional study of GKL-006 Injection and transarterial chemoembolization in Hepatocellular Carcinoma (HCC) and Unresectable Hepatocellular Carcinoma, sponsored by Beijing Gene Key Life Technology Co., Ltd. Completed at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Beijing Gene Key Life Technology Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Apr 2024, registered Sep 2026).
Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,310 studies in Carcinoma, Hepatocellular with a site in China — 486 open to participants now, 558 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Enrollment
956th of 1,034
13 · median 78
Started
2024
with 139 others
Phase 1
138 of 1,310
60 open now
Registered
1,302nd of 1,310
by date

Among the 1,310 studies in Carcinoma, Hepatocellular with a site in China, this one is the 956th largest by enrollment of the 1,034 interventional ones that give a count, is one of 140 that started in 2024, is one of 138 in phase 1, and was the 1,302nd registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

486 of the 1,310 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

481 more — sign in →

All 486 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,310 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

This Phase Ia study evaluated the safety and tolerability of a single escalating dose via intravenous infusion of the autologous invariant natural killer T cells (iNKT-cell) product GKL-006 in combination with transarterial chemoembolisation (TACE) in participants with unresectable hepatocellular carcinoma (uHCC). The study aimed to characterise dose-limiting toxicities (DLT), determine the maximum tolerated dose (MTD), and assess pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumour activity.

Read the detailed description

The study used a 3+3 dose-escalation design with three GKL-006 dose levels: (1.0±0.3)×10\^8, (3.0±0.9)×10\^8, and (9.0±2.7)×10\^8 iNKT cells/m\^2. Each cohort was planned to include three participants receiving GKL-006 plus TACE and one concurrent participant receiving TACE alone. All participants underwent one TACE procedure during the 28-day treatment period, which also served as the DLT observation period. Nineteen participants were screened and 13 were enrolled; one enrolled participant underwent leukapheresis but did not receive the cell infusion, leaving 12 participants who completed the protocol-specified treatment and DLT evaluation. After treatment, efficacy was assessed every 8 weeks, with continued safety, imaging, and survival follow-up.

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)
  • Unresectable Hepatocellular Carcinoma

Keywords

  • invariant natural killer T cells
  • iNKT cells
  • GKL-006
  • Unresectable Hepatocellular Carcinoma
  • TACE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily participates and provides written .
  • Aged ≥18 years, male or female.
  • Unresectable primary hepatocellular carcinoma (HCC) confirmed by histology, cytology, or imaging (dynamic CT or MRI). Unresectable disease includes technically unresectable disease or disease for which surgery is not feasible or is declined for other reasons.
  • CNLC stage II-IIIa.
  • Suitable for TACE and total tumour volume ≤50% of the liver volume.
  • At least one measurable HCC lesion per .
  • Tumour confined to the liver, with no extrahepatic spread or major vascular invasion (Vp3 or Vp4 portal vein tumour thrombus).
  • score ≤9 within 7 days before enrolment.
  • performance status of 0-2
  • ≥24 weeks.
  • Adequate haematologic and organ function:

    • WBC ≥2 × 10\^9/L;
    • ≥90 g/L;
    • ≥1.5 × 10\^9/L;
    • ≥50 × 10\^9/L;
    • PT or ≤2 × ;
    • serum creatinine ≤ULN;
    • and ALT ≤5 × ULN;
    • total ≤3 × ULN.
  • For patients with or infection, viral load must not exceed the lower limit of detection (HBV DNA ≤2,000 IU/mL and HCV RNA ≤100 IU/mL).
  • No radiotherapy, chemotherapy, targeted therapy, or therapy within 4 weeks before screening.
  • Participants of must use at least one medically accepted method during study treatment and for 6 months after treatment.
  • Able to communicate with investigators, comply with study visits, and understand and follow study requirements.

Exclusion criteria

Exclusion Criteria:

  • to immunotherapy or related medications.
  • Another within the previous 5 years or a concurrent uncontrolled malignancy, except cured basal cell carcinoma, carcinoma in situ, or breast cancer with no recurrence for >3 years after curative surgery.
  • History of organ transplantation.
  • Any to TACE, as determined by the investigator.
  • or cytologically confirmed combined HCC-cholangiocarcinoma, fibrolamellar HCC, sarcomatoid HCC, or another mixed carcinoma.
  • Active, known, or suspected disease.
  • Systemic (>10 mg/day prednisone or equivalent) or other therapy within 4 weeks before screening.
  • Infiltrative tumour growth or extrahepatic on imaging.
  • Hepatic encephalopathy.
  • Symptomatic ascites or pleural effusion.
  • History or current evidence of idiopathic pulmonary fibrosis, interstitial pneumonitis, pneumoconiosis, drug-induced pneumonitis, or active pneumonitis on screening CT.
  • Poorly controlled cardiovascular disease.
  • Uncontrolled hypertension despite medication (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg).
  • Urine protein ≥2+ within 7 days before enrolment with confirmed 24-hour urine protein >1.0 g.
  • Any of the following bleeding risks:
  • v5.0 Grade ≥2 bleeding within 4 weeks before enrolment;
  • tumour invasion of a major vessel or a high risk of life-threatening bleeding, as determined by the investigator;
  • gastrointestinal bleeding within 6 months;
  • known hereditary or acquired bleeding or thrombotic disorder.
  • Arterial or venous thromboembolic event within 6 months.
  • Signs or symptoms of intestinal or gastrointestinal obstruction within 1 month.
  • Active infection within 2 weeks before enrolment.
  • or ALT >5 × within 7 days before enrolment.
  • Congenital or acquired immunodeficiency, including infection; syphilis; or another serious active infection.
  • Pregnant or breastfeeding women.
  • Receipt of a or COVID-19 vaccine within 4 weeks before screening.
  • Participation in another interventional clinical trial.
  • Any serious concomitant disease, laboratory abnormality, psychiatric condition, or family or social circumstance that may compromise participant safety or interfere with data or sample collection, as determined by the investigator.
  • Any other condition that, in the investigator's opinion, makes the participant unsuitable for enrolment or study completion.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Active comparator
    TACE

    Participants will receive transarterial chemoembolization (TACE) alone according to the study protocol.

    Drug: transarterial chemoembolization

  • Experimental
    Low-Dose Cohort

    Participants will receive TACE and (1.0±0.3)×10\^8 iNKT cells/m\^2 of GKL-006 Injection sequentially according to the study protocol.

    Biological: GKL-006 Injection · Drug: transarterial chemoembolization

  • Experimental
    Medium-Dose Cohort

    Participants will receive TACE and (3.0±0.9)×10\^8 iNKT cells/m\^2 of GKL-006 Injection sequentially according to the study protocol.

    Biological: GKL-006 Injection · Drug: transarterial chemoembolization

  • Experimental
    High-Dose Cohort

    Participants will receive TACE and (9.0±2.7)×10\^8 iNKT cells/m\^2 of GKL-006 Injection sequentially according to the study protocol.

    Biological: GKL-006 Injection · Drug: transarterial chemoembolization

Interventions

  • Autologous iNKT cells collected and reinfused after in vitro cultivation.

  • Drugtransarterial chemoembolization

    A standard locoregional therapy for hepatocellular carcinoma.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose(MTD)of GKL-006

    The MTD determined from protocol-defined DLTs under the 3+3 dose-escalation design.

    Time frame: From the GKL-006 infusion until 28 days.

  2. Incidence of Dose-Limiting Toxicities (DLTs)

    Observe the dose limiting toxicity, and Incidence of dose-limiting toxicities(DLT) will be assessed

    Time frame: From GKL-006 infusion through Day 28

Secondary outcomes

  1. Incidence and Severity of Adverse Events

    Defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE V5.0).

    Time frame: From GKL-006 infusion though 28 days.

  2. Cmax

    maximum observed peripheral blood concentration of GKL-006 in trial participants within GKL-006 injection

    Time frame: From 1 hour pre-dose of GKL-006 injection through 12 weeks

  3. Tmax

    time to observed Cmax of GKL-006 in trial participants within GKL-006 injection

    Time frame: From 1 hour pre-dose of GKL-006 injection through 12 weeks

  4. AUC

    Pharmacokinetic characteristics of the area under the peripheral blood cell concentration-time curve

    Time frame: From 1 hour pre-dose of GKL-006 injection through 12 weeks

  5. t1/2z

    terminal elimination half-life of GKL-006

    Time frame: From 1 hour pre-dose of GKL-006 injection through 12 weeks

  6. Changes in Peripheral Blood Immune Cell Subsets

    Changes from baseline in NK cells (CD3-CD56+), activated NK cells (CD3-CD56+CD69+), CD8+ T cells, and MDSCs (CD11b+CD33+), assessed as cell counts and/or percentages.

    Time frame: From 1 hour pre-dose of GKL-006 injection through 12 weeks

  7. Changes in Plasma Cytokines and Cytotoxic Effector Molecules

    Changes from baseline in plasma IFN-γ, perforin, granzyme B, TNF-α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, and IL-13 concentrations.

    Time frame: From 1 hour pre-dose of GKL-006 injection through 12 weeks

  8. PFS

    from enrollment to disease progression assessed according to mRECIST and iRECIST or death from any cause, whichever occurs first.

    Time frame: Approximate 14 months

  9. DCR

    The rate of participants with a best overall response of CR, PR, or SD.

    Time frame: Approximate 14 months

  10. ORR

    The rate of participants with a best overall response of complete response (CR) or partial response (PR).

    Time frame: Approximate 14 months

  11. DOR

    The time from the first documented CR or PR to disease progression or death from any cause, whichever occurs first.

    Time frame: Approximate 14 months

  12. TTP

    From enrollment to disease progression

    Time frame: Approximate 14 months

  13. 1Y-OS

    The proportion of participants who are alive 1 year after enrollment.

    Time frame: Approximate 14 months

  14. OS

    The time from enrollment to death.

    Time frame: From enrollment to death, approximate 5 years.

07

Study locations

2 sites
  • Beijing Ditan Hospital Chaoyang Campus
    Beijing, Beijing Municipality 100015, China
  • Beijing Youan Hospital, Capital Medical University
    Beijing, Beijing Municipality 100069, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Apr 2025, 11 months.

Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 11 months is below that.

Counting every sponsor, half of 249 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 28, 2026
StartActual
Apr 16, 2024
Primary completionActual
Apr 9, 2025
CompletionActual
Dec 4, 2025
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07845266
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Apr 16, 2024
Primary completion
Apr 9, 2025
Completion
Dec 4, 2025
Last update
Sep 28, 2026

Study contacts

Jun Lv, MD
principal investigator · Beijing YouAn Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GKL-006

Start the discussion